SCHEMBL4528741

SCHEMBL4528741

CCN1C(=O)C(C(=O)OC)C(=O)c2cc(Nc3ccc(OC)cc3C)cc(C)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.40
USP2 O75604 1/20 0.37
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PIK3CA P42336 7/20 0.35
PRKDC P78527 7/20 0.35
MTOR P42345 4/20 0.35
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
P2RX7 Q99572 3/20 0.34
PIK3CD O00329 1/20 0.34
CSF1R P07333 1/20 0.34
PIK3CB P42338 1/20 0.34
MAPK9 P45984 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5095589 0.92 GAA (0.43) GAAUSP2AKR1C3AKR1C2ALDH1A1
SCHEMBL5059322 0.67 TDP2 (0.40) GAAUSP2MEN1KMT2AALDH1A1
SCHEMBL5095593 0.64 GAA (0.43) GAAMEN1KMT2AAKR1C3AKR1C2
SCHEMBL25634740 0.63 GAA (0.80) GAAMEN1KMT2AAKR1C3AKR1C2
SCHEMBL10851025 0.60 GAA (0.60) GAAMEN1KMT2APRKDCALDH1A1
SCHEMBL25633969 0.60 GAA (0.65) GAAMEN1KMT2AAKR1C3AKR1C2
SCHEMBL502786 0.60 GAA (1.00) GAAMEN1KMT2AAKR1C3AKR1C2
SCHEMBL6999192 0.60 GAA (0.75) GAAMEN1KMT2AAKR1C3AKR1C2
SCHEMBL2952972 0.60 GAA (0.75) GAAMEN1KMT2AAKR1C3AKR1C2
SCHEMBL10834109 0.60 CDC25B (0.65) GAAAKR1C3AKR1C2ALDH1A1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498341-B2 antidiabetic agents; type 2 diabetes SANOFI AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-03 US disclosed
US-7402674-B2 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) 2008-07-22 US disclosed
US-20050182085-A1 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-08-18 US disclosed
US-20050182086-A1 antidiabetic agents; type 2 diabetes AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182086-A1 antidiabetic agents; type 2 diabetes SLC5A2, SLC5A1, SLC2A2 GAA 671/4885USP2 2175/4885MEN1 2746/4885
US-20050182085-A1 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments SLC5A2, CYP2A7, GLS GAA 413/4885USP2 2156/4885MEN1 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.